NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
Healthcare
$2.55 +1.43%
+$0.06 today
- Market cap
- $113.04M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
52W Low $1.62High $5.06
Volume 1.39M
Average 1.27M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$14.11M
FY 2025 · Annual
Investing Cash Flow
-$2.81M
FY 2025 · Annual
Financing Cash Flow
$23.28M
FY 2025 · Annual
+211.0% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.79M | 3.63M | 387K | 486K | 228K |
| Change in Working Capital | (4.9M) | 699K | 5.16M | 5.29M | 1.41M |
| Accounts Receivables | 831K | 0 | 0 | 0 | 48K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (19K) | (1.61M) | 2.66M | (5.22M) | 113K |
| Other Working Capital | (5.71M) | 2.31M | 2.51M | 10.51M | 1.25M |
| Other Non-Cash Items | 52.47M | (4.33M) | 2.94M | 8.71M | 12.73M |
| Operating Cash Flow | (37.7M) | (39.76M) | (21.66M) | (10.64M) | (14.11M) |
| Capital Expenditures | (7K) | (10K) | (3K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (2.38M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (432K) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7K) | (10K) | (3K) | 0 | (2.81M) |
| Debt Repayment | (1.28M) | 9.5M | (3.09M) | (1.5M) | 7.42M |
| Common Stock Issued | 36.98M | 22.7M | 8.12M | 5.91M | 15.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 27.75M | 10K | 0 | 3.07M | 0 |
| Financing Cash Flow | 63.46M | 32.21M | 6.2M | 7.49M | 23.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.75M | (7.55M) | (15.46M) | (3.15M) | 6.35M |
| Free Cash Flow | (37.71M) | (39.77M) | (21.66M) | (10.64M) | (14.11M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$28.6M
+ D&A$143.0K
+ Stock-Based Comp$228.0K
+ Deferred Tax$0
+ Working Capital$1.4M
+ Other Non-Cash$12.7M
= Operating Cash Flow-$14.1M
- Capex$0
= Free Cash Flow-$14.1M
Analysis
FY2025 free cash flow is -$14.1M. FCF conversion is 49.3% of net income. Operating cash flow was -$14.1M, with capex of $0. The largest bridge item is Other Non-Cash at $12.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEF 14A | DEF 14A filing | Nov 5, 2026 | |
| DEFA14A | DEFA14A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 8-K | Current report | Nov 2, 2026 |
Does NRXP generate free cash flow?
NRx Pharmaceuticals, Inc. (NRXP) generated -$14.11M of free cash flow in fiscal 2025.
How much operating cash flow does NRXP produce?
Operating cash flow was -$14.11M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.